摘要:
The invention relates to the use, or methods (especially with regard to animals, especially human, that are in need of such treatment) comprising the use, of an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from the group consisting of Schisandra , Illicium , Kadsura, Steganotaenia and Magnolia , alone or as supplement, as active ingredient in the regulation of body weight and/or fat loss and/or for the management of obesity, either in humans or in animals, to the use of said extract and/or natural compound(s) or mixtures in the manufacture of a pharmaceutical or nutraceutical formulation for the regulation of body weight and/or fat loss and/or for the management of obesity either in humans or in animals. The above extract and/or compound(s) can further be used to reduce one or more adverse metabolic parameters in a subject. The invention relates also to said extract and/or compound(s) for use in the treatment or in the preparation of a medicament for the treatment of obesity, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in the regulation of body weight and/or fat loss and/or for the management of obesity.
摘要:
The present invention relates to therapeutic formulations based on pumpkin products, in particular to encapsulated formulations for oral administration. A product of the invention comprises a hard gelatin capsule which encloses a unit dose of a formulation which comprises at least 50% by weight of one or more pumpkin product.
摘要:
A pharmaceutical composition for treating diabetes and preparation method thereof. The pharmaceutical composition according to the present invention is composed of raw material drugs including radix of Rehmannia glutinosa Libosch; radix of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao, Astragalus membranaceus (Fisch.) Bge; rhizoma of Dioscorea opposita Thunb; radix of Pueraria lobata (Willd.) Ohwi Pueraria thomsonii Benth; radix of Trichosanthes kirilowii Maxim, Trichosanthes rosthornii Harms; stigma of Zea mays L; fructus of Schisandra sphenanthera Rehd. Et Wils. and glibenclamide. The pharmaceutical composition according to the present invention has the functions of nourishing kidney-Yin, benefiting vital energy and promoting the secretion of saliva, and is used in treating diabetes of deficiency in both vital energy and Yin, namely non insulin-dependent diabetes.
摘要:
A method for treating a mammal having oral tissue inflammation is provided, where the inflamed oral tissue is contacted with a safe, efficacious, non-irritating oral composition having an anti-inflammatory agent comprising a magnolia extract. The magnolia anti-inflammatory active ingredient reduces one or more mediators of inflammation and reduces inflammation in oral tissue. The oral composition can be in the form of a mouth rinse; dentifrice, including toothpaste, gels, powders, lozenges; medicament gel; animal products; and the like.
摘要:
The present invention provides for pharmaceutical compositions that includes a triterpene (e.g., betulin) and an essential oil (Vicks(R) Vapor Rub). The present invention also provides for a cosmetic formulation that includes a triterpene (e.g., betulin) and an essential oil (Vicks(R) Vapor Rub). The present invention also provides a method of treating a fungal infection that includes administering (e.g., topically applying) an effective amount of the pharmaceutical composition to the tissue afflicted with the fungal infection, or the tissue at risk of being afflicted with the fungal infection.
摘要:
Compositions, including formulations, of plants for the treatment of Inflammatory Bowel Disease, Irritable Bowel Syndrome, and inflammatory and other related conditions, such as arthritis, are disclosed. The formulations consist of one or both of the two herbs Chen Pi Citrus reticulata and Wu Mei Prunus mume , which, according to the invention, possess significant cytokine TNF- alpha inhibitory activity. The formulations also may include one or more of the following herbs which, according to the invention, inhibit PGE2: Hou Po Magnoliae officinalis , Huang Bai Phellodendron chinense , Huang Lian Coptis chinensis , Huo Xiang Agastaches rugosa , Pao Jiang Zingiberis officinalis , Qin Pi Fraxinus rynchophylla , and Zhi Gan Cao Glycyrhizae inflata .
摘要翻译:公开了用于治疗炎症性肠病,肠易激综合征以及炎症和其它相关病症如关节炎的植物的组合物,包括制剂。 该制剂由两种草药陈皮柑橘和乌梅杏仁组成,根据本发明,它们具有显着的细胞因子TNF-α抑制活性 。 制剂还可以包括以下一种或多种草药,根据本发明,本发明抑制PGE2:厚朴木兰,黄柏黄柏,黄莲 > ensis ensis ensis,,Ag rug rug rug,i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i >甘草泡囊 i>。
摘要:
The present invention relates to a nutraceutical or pharmaceutical homogeneous composition having antibacterial, antifungal, antiviral, immune system reinforcing, anticancer and antiparasitic characteristics. Said homogeneous composition comprises all of the components of hot pepper, black mulberry, aniseed, urtica urens, fig and olive at specific weight proportions or specific combination mixtures with each other.